We are live on ! Find out more
AMRI

Albany Molecular Research Inc
AMRI

Delisted

AMRI was delisted on the 31st of August, 2017.

131 hedge funds and large institutions have $571M invested in Albany Molecular Research Inc in 2015 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 51 increasing their positions, 33 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more call options, than puts

Call options by funds: $3.33M | Put options by funds: $1.48M

55% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 33

18% more capital invested

Capital invested by funds: $484M → $571M (+$87.1M)

0% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 20

1% less funds holding

Funds holding: 132131 (-1)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
131
Holders Change
-1
Holders Change %
-0.76%
% of All Funds
3.49%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
20
Increased
51
Reduced
33
Closed
20
Calls
$3.33M
Puts
$1.48M
Net Calls
+$1.85M
Net Calls Change
-$527K
Name Holding Trade Value Shares
Change
Change in
Stake
Dimensional Fund Advisors
1
Dimensional Fund Advisors
Texas
$40.6M -$6.68M -392,174 -15%
PIP
2
Permian Investment Partners
Texas
$33.4M -$6.02M -353,400 -16%
BFA
3
BlackRock Fund Advisors
California
$32.4M +$1.79M +104,831 +6%
Wellington Management Group
4
Wellington Management Group
Massachusetts
$31.3M +$2.68M +157,206 +10%
Goldman Sachs
5
Goldman Sachs
New York
$28.8M +$27.6M +1,622,297 +9,972%
VNIM
6
Vaughan Nelson Investment Management
Texas
$25.9M +$2.25M +131,900 +10%
OWP
7
Obermeyer Wealth Partners
Colorado
$24.6M +$18.7M +1,096,870 +364%
VAM
8
Visium Asset Management
New York
$24.3M -$31M -1,820,000 -57%
EWM
9
Evercore Wealth Management
New York
$22.9M
RA
10
Royce & Associates
New York
$22.7M +$941K +55,200 +4%
HM
11
HealthCor Management
New York
$22.4M -$5.54M -325,000 -20%
RHJA
12
Rice Hall James & Associates
California
$20.3M +$19.6M +1,150,801 New
Vanguard Group
13
Vanguard Group
Pennsylvania
$18M +$2.42M +142,170 +16%
ACM
14
American Capital Management
New York
$17.6M -$369K -21,630 -2%
EAM
15
EverPoint Asset Management
Connecticut
$15.8M +$15.3M +900,000 New
Allianz Asset Management
16
Allianz Asset Management
Germany
$13.9M -$2.09M -122,823 -13%
BIT
17
BlackRock Institutional Trust
California
$13.5M +$109K +6,382 +0.8%
Bank of Montreal
18
Bank of Montreal
Ontario, Canada
$12.4M +$11.9M +696,025 +11,676%
Morgan Stanley
19
Morgan Stanley
New York
$10.6M -$399K -23,438 -4%
HVC
20
Healthcare Value Capital
New Jersey
$9.55M -$951K -55,800 -9%
State Street
21
State Street
Massachusetts
$7.23M +$278K +16,324 +4%
BM
22
Bridger Management
New York
$7.04M +$6.82M +400,056 New
NAM
23
Netols Asset Management
Wisconsin
$6.95M -$191K -11,192 -3%
Northern Trust
24
Northern Trust
Illinois
$6.38M +$1.16M +67,864 +23%
RFC
25
Russell Frank Company
Washington
$5.99M -$1.18M -69,183 -17%

AMRI Hedge Fund Activity: Q1 2015 in Review

131 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Albany Molecular Research Inc (AMRI) for Q1 2015, worth a combined $571M — up 18% from $484M a quarter earlier.

Fund positioning in AMRI was balanced in Q1 2015: 20 funds opened new positions, 20 closed out, 51 added to existing stakes and 33 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $27.6M. The largest seller was Visium Asset Management, cutting an estimated $31M.

  • 131 institutional investors held Albany Molecular Research Inc (AMRI) as of Q1 2015, down from 132 in Q4 2014.
  • Funds reported $571M of Albany Molecular Research Inc stock for Q1 2015, up 18% quarter-over-quarter.
  • 20 funds opened new Albany Molecular Research Inc positions in Q1 2015 and 20 closed out, a net change of 0 holders.
  • The largest Albany Molecular Research Inc buyer in Q1 2015 was Goldman Sachs, an estimated $27.6M added.
  • The largest Albany Molecular Research Inc seller in Q1 2015 was Visium Asset Management, an estimated $31M sold.

Based on aggregated 13F filings for Q1 2015.